Cite
HARVARD Citation
Fizazi, K. et al. (2022). Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. Journal for immunotherapy of cancer. 10 (8), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Fizazi, K. et al. (2022). Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. Journal for immunotherapy of cancer. 10 (8), p. . [Online].